Skip to main content
PLOS One logoLink to PLOS One
. 2021 Feb 24;16(2):e0247457. doi: 10.1371/journal.pone.0247457

Prevalence of clinical signs of possible serious bacterial infection and mortality associated with them from population-based surveillance of young infants from birth to 2 months of age

Dhruv Puri 1, Yasir Bin Nisar 1,*, Antoinette Tshefu 2, Adrien Lokangaka Longombe 2, Fabian Esamai 3, Irene Marete 3, Adejumoke Idowu Ayede 4, Ebunoluwa A Adejuyigbe 5, Robinson D Wammanda 6, Shamim Ahmad Qazi 7, Rajiv Bahl 1
Editor: Claudia Marotta8
PMCID: PMC7904202  PMID: 33626090

Abstract

Background

Community-based data on the prevalence of clinical signs of possible serious bacterial infection (PSBI) and the mortality associated with them are scarce. The aim was to examine the prevalence for each sign of infection and mortality associated with infants in the first two months of life, using community surveillance through community health workers (CHW).

Methods

We used population-based surveillance data of infants up to two months of age from the African Neonatal Sepsis Trial (AFRINEST). In this study, CHWs visited infants up to 10 times during the first two months of life at five sites in three sub-Saharan African countries. CHW assessed the infant for signs of infection (local or systemic) and referred infants who presented with any sign of infection to a health facility. We used a longitudinal analysis to calculate the risk of death associated with the presence of a sign of infection at the time of the visit until the subsequent visit.

Results

During the first two months of their life, CHWs visited 84,759 live-born infants at least twice. In 11,089 infants (13.1%), one or more signs of infection were identified, of which 237 (2.1%) died. A sign of infection was detected at 2.1% of total visits. In 52% of visits, infants had one or more sign of systemic infection, while 25% had fast breathing in 7–59 days period and 23% had a local infection. All signs of infection, including multiple signs, were more frequently seen in the first week of life. The risk of mortality was very low (0.2%) for local infections and fast breathing in 7–59 days old, it was low for fast breathing 0–6 days old (0.6%), high body temperature (0.7%) and severe chest indrawing (1.0%), moderate for low body temperature (4.9%) and stopped feeding well/not able to feed at all (5.0%) and high for movement only when stimulated or no movement at all (10%) and multiple signs of systemic infection (15.5%). The risk of death associated with most clinical signs was higher (1.5 to 9 times) in the first week of life than at later age, except for low body temperature (4 times lower) as well as high body temperature (2 times lower).

Conclusion

Signs of infections are common in the first two months of life. The mortality risk differs with clinical signs and can be grouped as very low (local infections, fast breathing 7–59 days), low (fever, severe chest indrawing and fast breathing 0–6 days), moderate (low body temperature and stopped feeding well/not able to feed at all) and high (for movements only on stimulation or no movements at all and multiple signs of infection). New treatment strategies that consider differential mortality risk could be developed and evaluated based on these findings.

Clinical trial registration

The trial was registered with Australian New Zealand Clinical Trials Registry under ID ACTRN 12610000286044.

Background

In 2018, an estimated 5.3 million under-five-year-old deaths occurred globally and 2.5 million died in the first four weeks of life [1]. One-third of these neonatal deaths occurred on the first day of life and three-quarters in the first week. Most deaths occurred in low-and middle-income countries (LMIC) with sub-Saharan Africa leading the world in both neonatal and under-five mortality rates [1]. Prematurity, birth asphyxia and neonatal infections are the major causes of neonatal deaths globally [1,2]. Maternal sepsis during pregnancy, labour and post-partum and post caesarean section infections also result in neonatal deaths in low resource settings [35]. The overall burden of possible serious bacterial infection (PSBI) in young infants of LMICs is substantial [6,7]. A systematic review and meta-analysis that included data from 22 studies, for 259,944 neonates and 20,196 PSBI cases reported pooled estimate of PSBI incidence risk as 7.6% and a case fatality rate (CFR) of 9.8% (3). It estimated that 6.9 million cases of PSBI needed treatment in 2012. In a large multicentre prospective study in Argentina, Guatemala, India, Kenya, Pakistan, Zambia, the incidence of PSBI ranged from 3% in Zambia to 36% in Pakistan in a cohort of 248,539 live births in the first six weeks of life. The incidence of PSBI during the first 6 weeks of life varied 10 fold between sites [7].

Over the past two decades, there has been substantial simplification in identifying PSBI using symptoms and clinical signs. In the 1990s, a multicentre study conducted in Ethiopia, The Gambia, The Philippines, Papua New Guinea identified 13 predictors of serious infection, which should be referred to a hospital [8]. These signs (convulsions, fast breathing defined as the respiratory rate of 60 breaths per minute or more, severe chest indrawing, nasal flaring, grunting, bulging fontanelle, pus drainage from the ear, temperature ≥37.5°C or <35.5°C or feels cold, umbilical redness extending to the skin, many or severe skin pustules, lethargy or unconsciousness, less than normal movement) were included in the first Integrated Management of Childhood Illness (IMCI) chart booklet in 1997 to identify PSBI in 7–59 days old young infants [9]. It was challenging to train and maintain first-line health workers’ skills for all signs. In 2008, another study conducted in Bangladesh, Bolivia, Ghana, India, Pakistan, and South Africa found that seven signs had a sensitivity of 85% and specificity of 75% to identify PSBI in the first week of life and sensitivity of 74% and specificity of 79%) in 7-59-day-old infants [10]. The revised IMCI chart booklet in 2014 used seven signs (not feeding well, convulsions, movement only when stimulated or no movement at all, fast breathing, severe chest indrawing, the temperature of ≥37.5°C or <35.5°C) to identify PSBI in young infants for a referral to a hospital [11].

Unfortunately, many families in low resource settings do not accept referral advice for a hospital [1215]. Four trials were conducted in Asia and Africa to evaluate the effectiveness of simplified antibiotic regimens on an outpatient basis when the referral was not feasible [1619]. These data showed that young infants with only fast breathing had a negligible death rate and those categorized as clinical severe infection (stopped feeding well, movement only when stimulated, severe chest indrawing, axillary temperature of ≥38°C or<35.5°C) had a death rate of 1–2%. Critically ill young infants (convulsions, not able to feed at all, no movement at all) were not included in these studies. This data contributed to a World Health Organization guideline to manage PSBI when a referral was not feasible [20]. It recommended fast breathing in 7–59 days old young infants to be treated with oral amoxicillin on an outpatient basis without a referral, and clinical severe infection to be treated with injectable gentamicin plus oral amoxicillin on an outpatient basis when the referral was not feasible [20].

Community-based data using specific clinical signs for identifying infections and associated mortality in newborns and young infants are scarce. Bang et al from India reported that identification by community health workers (CHW) of any two out of seven signs simultaneously (reduced or stopped sucking; weak or no cry; limbs becoming limp; vomiting or abdominal distension; baby cold to touch; severe chest indrawing; umbilical infection) predicted a sepsis death in a newborn [21]. Another study from Nepal reported CHW experience of identifying PSBI from the community and identified two signs concurrently having a higher CFR [22]. Several studies, validated the clinical signs used by CHW to identify serious infections in the community from Bangladesh [2325] and one from Nepal validated signs for umbilical sepsis only at the community level [26]. None of the studies reported mortality for each sign separately and all reported a much smaller number of newborns followed in the community, compared to AFRIcan NEonatal Sepsis Trial (AFRINEST) [27,28]. Secondly, all studies were conducted in Asia.

In the AFRINEST community surveillance was carried out by CHW who visited each newborn at home several times up to two months of age to identify sick young infants with signs of PSBI We used this population-based data to conduct secondary analysis to assess the prevalence of each clinical sign and its association with mortality.

Methods

Study design

We used population-based surveillance data from the AFRINEST which was a prospective randomized controlled trial over five sites in three sub-Saharan African countries–Democratic Republic of the Congo (DRC), Kenya, and Nigeria [16,17]. The methodology of the trial has been published [27,28]. Briefly, two trials were conducted—one trial evaluated the simplified antibiotic regimens for management of young infants up to 2 months of age with clinical severe infection when hospital admission was not feasible [17], and the other compared oral antibiotic and injectable plus oral antibiotic therapies for fast breathing in young infants [16].

Data collection and follow-up

In AFRINEST, we established a population-based surveillance system at all five study sites to identify pregnant women, collect information on the birth status and then followed live births for up to two months of age through community health workers (CHW). CHWs in DRC and Kenya and Community Health Extension Workers (CHEWs) in Nigeria conducted follow up visits scheduled on days 1, 3, 7, 14, 21, 28, 35, 42, 49, and 59 after birth and assessed young infants for signs of infection (Panel 1). The CHEWs had 2–3 years formal training compared to CHWs who had been trained for a few weeks [28]. Infants with any sign of infection were referred to a health facility or hospital for further assessment and management. Study nurses at health facilities examined sick infants identified by CHW/CHEWs to validate signs of infection. Infants with any sign of infection were referred to hospital for treatment and families who refused referral were offered simplified antibiotic regimens on an outpatient basis [27,28]. Quality assurance was ensured by close monitoring and periodic training of all CHWs/CHEWs in WHO/UNICEF caring for newborns in the community training module and the study procedures [2729].

Panel 1. Classification for this analysis using signs of infection in young infants aged 0 to 59 days as recorded by community health workers and community health extension workers.

    • Local infection as defined by pus in the umbilicus, skin, or eye
    • Fast breathing as defined by respiratory rate of 60 or more breaths per minute (in the first 7–59 days of life)
Signs of Systemic Infection
    • Fast breathing as defined by respiratory rate of 60 or more breaths per minute (in the first 0–6 days of life)
    • Stopped feeding well or unable to feed according to the mother
    • Reported convulsions
    • High body temperature defined as an axillary temperature of 37.5°C and above
    • Low body temperature defined as an axillary temperature of below 35.5°C
    • Severe chest indrawing
    • Movement only on stimulation or no movement at all

Study exposure variables and outcome

At each visit, CHWs/CHEWs assessed young infants for signs of infection (Panel 1) and recorded their observations in a case report form. These signs, which we considered as study exposure variables, were classified into three mutually exclusive categories of ‘no sign of infection’, ‘signs of local infection’, and ‘fast breathing in 7–59 days old’, ‘signs of systemic infection’ (Panel 1).

The study outcome was the status of the child as alive or death (all-cause) recorded by CHWs/CHEWs during each visit. The association of other information such as study site, sex of the infant, maternal age, place of delivery and weight at birth with the study outcome was investigated.

Ethical considerations

The AFRINEST study was approved by the site institutional ethics review committees and the WHO Research Ethics Review Committee. We obtained written and witnessed informed consent from parents/caregiver.

Statistical analysis and definitions

Data analysis was performed using Stata™, Version 14 (Stata-Corp, College Station, TX, USA). For analysis purposes, if a sign was recorded as missing at a particular visit in the database, it was inferred to be the same as the immediately preceding visit. We defined the period between two visits as an infant-period. This was usually seven days (between two consecutive visits by a CHW/CHEW to assess the same young infant), except in the case of the first week of life (shorter than 7 days) and the last 10 days of the second month (longer than 7 days).

We selected infants up to 2 months of age with at least two visits by CHWs/CHEWs. Missing outcomes were inputted under the assumption that infants whose outcome was known in a later visit could be assumed to be alive at prior visits. Young infants whose information on signs of infection at either of the two visits immediately preceding outcome was not available were excluded from the analysis. We used a longitudinal analysis to calculate the risk of death associated with the presence of a sign of infection at the time of visit until the subsequent visit expressed as a percentage. Presence of each sign of infection was calculated as the number of young infants with a specific sign of infection divided by the total number of infant-periods followed and expressed as per 1000 infant-periods.

Results

We registered a total of 95299 pregnant women from all sites. Of these, we identified 85592 (89.8%) live births and among live births, 84759 infants (99%) were visited at least two times (of a maximum possible of 10) by CHWs/CHEWs and were included in analyses. One or more signs of infection were identified at least once in 11,089 infants (13.1%), of which 237 (2.1%) died. Of the 73670 infants with no sign of infection, 350 (0.5%) died (Fig 1).

Fig 1. Flow diagram of the exclusion criteria to establish the study population.

Fig 1

CHW: Community health worker. CHEW: Community health extension worker.

Fig 2 shows (a) presence of any sign of infection, and (b) the proportion of single or multiple signs of infection among young infants at the time of visits. A sign of infection was detected at 2.1% of visits. In 52% of visits, infants had one or more sign of systemic infection, while 25% had fast breathing in 7–59 days period and 23% had a local infection.

Fig 2.

Fig 2

a) Cumulative presence of any sign of infection in the first 2 months of life during follow-up visits by infant-periods, b) Proportion of individual and multiple signs of infection in infants who had any sign of infection. There were 616,421 infant-periods of follow up and in 13,260 (2.1%) of infant-periods, the infant had a sign of infection.

All signs of infection including local infections, single and multiple signs of systemic infection were frequently seen in the first week of life (Table 1). Local infections were most common in the second (16/1000) and third week (14/1000) of life, fast breathing (10-17/1000) and stopped feeding well/not able to feed at all (1/1000) were commonest in the first three weeks of life and severe chest indrawing was more frequent in the first 4 weeks of life (2-4/1000). High body temperature (9-10/1000), low body temperature (2-8/1000) and multiple signs (6/1000) were observed most commonly in the first week of life. Movement only on stimulation/no movement at all and convulsions was infrequently seen.

Table 1. Frequency of signs of infection by age of assessment (per 1000 infants) reported by CHWs/CHEWs*.

Number of infants Young infants assessed after birth on
Day 1 47471 Day 3 56279 Day 7 63817 Day 14 69057 Day 21 71905 Day 28 74024 Day 35 76202 Day 42 78189 Day 49 79407 Day 59 79008
n (per 1000 infants) n (per 1000 infants) n (per 1000) n (per 1000) n (per 1000) n (per 1000) n (per 1000) n (per 1000) n (per 1000) n (per 1000)
    Local infections 162 (4) 392 (7) 876 (14) 822 (12) 442 (6) 236 (3) 154 (2) 97 (1) 59 (1) 21 (<1)
    Fast breathing (7–59 Days) NA NA 1001 (16) 933 (14) 603 (8) 347 (5) 215 (3) 152 (2) 123 (2) 59 (1)
Signs of systemic infection
    Fast breathing (0–6 Days) 472 (10) 968 (17) NA NA NA NA NA NA NA NA
    High body temperature 418 (9) 537 (10) 336 (5) 275 (4) 182 (3) 124 (2) 106 (1) 99 (1) 9 (<1) 59 (1)
    Severe chest indrawing 107 (2) 226 (4) 204 (3) 214 (3) 192 (3) 134 (2) 115 (2) 75 (1) 73 (1) 22 (<1)
    Low body temperature 391 (8) 133 (2) 85 (1) 58 (1) 25 (<1) 14 (<1) 11 (<1) 10 (<1) 7 (<1) 3 (<1)
    Stopped feeding well or not feeding at all 58 (1) 79 (1) 37 (1) 47 (1) 30 (<1) 17 (<1) 13 (<1) 9 (<1) 11 (<1) 8 (<1)
    Movement only when stimulated or no movement at all 8 (<1) 11 (<1) 11 (<1) 6 (<1) 3 (<1) 4 (<1) 3 (<1) 2 (<1) 2 (<1) 3 (<1)
    Reported convulsions 20 (<1) 17 (<1) 12 (<1) 12 (<1) 9 (<1) 14 (<1) 5 (<1) 6 (<1) 0 (0) 0 (0)
    Multiple signs of systemic infection 278 (6) 302 (6) 118 (2) 97 (1) 72 (1) 54 (1) 27 (0) 36 (0) 23 (0) 14 (0)

* CHW: Community health worker; CHEW: Community health extension worker.

† 3261 local infections were reported, 498 (15.3%) umbilical infections, 1808 (55.4%) skin infections, 817 (25.1%) eye infections and 138 (4.2%) mixed local infections.

‡NA: Not applicable.

Fig 3 shows a clear gradation of risk of mortality from negligible with no signs followed by local infections, fast breathing, high body temperature, severe chest indrawing, whereas a higher risk of death was observed for low body temperature, and stopped feeding well/not able to feed at all. The highest risk of death was observed with the combination of signs of systemic infection. Additionally, we also observed a time trend for risk of death. For local infections, fast breathing, severe chest indrawing, stopped feeding well/not able to feed at all, the risk of death was highest in the first week of life. For multiple signs, the risk of death was highest in the first two weeks of life.

Fig 3. Distribution of risk of mortality associated with signs of infection† (per 1000 infant-periods) in the first two months of life.

Fig 3

† ‘Reported convulsions’ was excluded from the figure as no deaths occurred in young infants with only convulsions. ‘Movement only when stimulated or no movement at all’ was excluded due to low prevalence (<20 cases) per visit. * These children had multiple signs of systemic infection.

Table 2 shows that the signs have different levels of mortality by age. The risk of mortality was very low (0.2%) for local infections and fast breathing in 7–59 days old, it was low for fast breathing 0–6 days old (0.6%), high body temperature (0.7%) and severe chest indrawing (1.0%), moderate for low body temperature (4.9%) and stopped feeding well/not able to feed at all (5.0%) and high for movement only when stimulated or no movement at all (10%) and multiple signs of systemic infection (15.5%). The risk of death associated with most clinical signs was higher (1.5 to 9 times) in the first week of life than at later age, except for low body temperature (4 times lower) as well as high body temperature (2 times lower).

Table 2. Number of deaths by infant-periods of follow up and risk of death (%) by clinical signs stratified by 0–6 days and 7–59 days of life.

0–6 days of life 7–59 days of life Total
Clinical assessment by CHWs/CHEWs Deaths/infants-period Risk of death % (95% CI) Deaths/infants-period Risk of death % (95% CI) Deaths/infants-period Risk of death % (95% CI)
No Sign of infection 245/53279 0.5 (0.4, 0.5) 105/549882 0.02 (<0.1, <0.1) 350/603161 0.1 (0.1, 0.1)
    Local infections 4/453 0.9 (0.2, 2.2) 3/2645 0.1 (0.1, 0.3) 7/3098 0.2 (0.1, 0.5)
    Fast breathing (7–59 days) NA NA 6/3293 0.2 (0.1, 0.4) 6/3293 0.2 (0.1, 0.4)
Signs of Systemic Infection
    Fast breathing (0–6 days) 8/1429 0.6 (0.2, 1.1) NA NA 8/1429 0.6 (0.2, 1.1)
    High body temperature 4/952 0.4 (0.1, 1.1) 11/1184 0.9 (0.5, 1.7) 15/2136 0.7 (0.4, 1.2)
    Severe chest indrawing 6/331 1.8 (0.7, 3.4) 7/993 0.7 (0.3, 1.4) 13/1324 1.0 (0.5, 1.7)
    Low body temperature 14/504 2.8 (1.5, 4.6) 20/185 10.8 (6.7, 16.2) 34/689 4.9 (3.4, 6.8)
    Stopped feeding well or not able to feed at all 11/130 8.5 (4.3, 14.6) 3/151 2.0 (0.4, 5.7) 14/281 5.0 (2.7, 8.2)
    Movement only when stimulated or no movement at all 2/14 14.3 (1.8, 42.8) 2/26 7.7 (0.9, 25.1) 4/40 10.0 (2.8, 23.7)
    Reported convulsions 0/37 - 0/58 - 0/95 -
    Multiple signs of systemic infection 85/496 17.1 (13.9, 20.7) 51/379 13.5 (10.2, 17.3) 136/875 15.5 (13.2, 18.1)

NA: Not applicable.

Discussion

Key findings

The population-based surveillance data of young infants from three sub-Saharan African countries has several important findings. First, one in seven young infants had at least one episode of either local or systemic infection when assessed by a CHW/CHEW at any visit during the first two months of life. Second, nearly half of the sick young infants identified at the community level had either fast breathing or local infections, followed by fever and chest indrawing that were seen more often than other signs such as stopped feeding well/not able to feed at all, low body temperature and multiple signs. CHWs didn’t find many young infants with movement only on stimulation/no movement at all or convulsions. Third, All signs of infection were frequently seen in the first week of life, but fever, low body temperature and multiple signs were most common in this age group. Fast breathing, chest indrawing, movement only on stimulation/no movement at all and feeding difficulty were common in the first three weeks of life. Fourth, there was a clear gradation of risk of death with various signs. It was a very low risk of death for local infections and fast breathing (7–59 days), low risk for fast breathing (0–6 days), high body temperature and severe chest indrawing, moderate risk for low body temperature and stopped feeding well/not able to feed at all, and high risk for movement only when stimulated or no movement at all and multiple signs of infection. Finally, the risk of death associated with most clinical signs was higher in the first week of life than at later age, except for low body temperature as well as high body temperature.

Our data showed a higher prevalence of signs of infection during the first two months of age compared to an earlier systematic review and meta-analysis of 22 studies, which reported incidence risk of PSBI as 7.6%. The incidence risk was slightly higher (8.4%) in studies with active follow-up using seven signs of infection (excluding local infection signs) [6]. Our higher prevalence could be due to the inclusion of local infection signs, which were included because it is a referral sign at the community level [30]. Second, we conducted active surveillance through home visits by CHWs/CHEWs up to 10 times during the first two months of life. In contrast, another prospective multi-country study reported the incidence of PSBI range from 3% to 36% in different countries in the first six weeks of life [7].

Implications of results

First, we found a higher frequency of signs of systemic infection during the first week of life. Also, we observed the highest risk of death in the same period and higher rates of death for most systemic infection signs in the same period. This fits in well with the global data reporting one-third of neonatal deaths occurring on the first day of life and three-quarters in the first week of life [1]. This highlights the need for identifying these sick newborns as soon as possible to provide them with appropriate treatment. The WHO postnatal guidelines recommend two home visits by a CHW in the first week of life to counsel mothers on the care of the newborn and identify sick newborns [31]. Although the reported median coverage of postnatal home visits for newborns has increased from 30% in 2009–2013 to 68% in 2014–2019, it is still not enough [32]. Identifying sick young infants is not enough, getting them to well-trained health workers and health facility to get appropriate treatment is critical. Unfortunately, data shows that a large number of families do not accept referral advice to go to a hospital [1619,33,34]. Families refuse referral due to cost of travel and hospitalization, distance, religious and cultural beliefs, lack of permission from husband or family elders, concerns around quality of care at the hospital, poor attitudes of health workers, and lack of child care/other logistical barriers [3537]. Thus more efforts are needed to overcome these barriers through family counselling, community engagement, improving the quality of care at the health facilities and reduce the number of referrals by providing care nearer to people’s homes.

Second, a young infant with low body temperature and high body temperature should receive care throughout the first two months of life. Although the frequency of low body temperature and high body temperature was higher in the first week of life, one cannot rule out the environmental factors as its reason. Newborns are more likely to be exposed to low environmental temperatures in the first week of life and conversely, some may be wrapped much more so in the first week of life. But having low or high body temperature after the first week of life is more likely to be linked to an infection. The risk of death was four times higher for low body temperature after the first week of life and two times higher with high body temperature after the first week of life, so it needs more attention. A systematic review based on 10 community studies in Southeast Asia found that the prevalence of neonatal hypothermia ranged from 11% to 92%, whereas in hospital-based studies from Africa it ranged from 8% to 85% [38]. Poor management of neonatal hypothermia may lead to severe sepsis and death [39,40]. CFR for hypothermia ranges from 8.5% to 52% [4146].

Third, our analyses showed mortality risk differ by each clinical sign of infection. In the 1997 and 2014 IMCI chart booklets, each sign included in the algorithm was given equal weight to identify sick young infants for referral [9,11]. The 2015 WHO PSBI guideline removed fast breathing (7–59 days) from the referral advice, but the other seven signs were all given equal weight for referral recommendation [20,47]. We could find one study in infants up to 6 weeks of life with PSBI signs that collected data from health facilities, which reported CFR for individual signs, 1% with high fever, 18% for hypothermia, 22% with feeding problem/stopped sucking or feeding, 25% with convulsions and 27% with multiple signs [7]. This data allows us to hypothesize that there is further room for improvement in risk stratification for management of PSBI in the current WHO guideline, so that the low mortality risk signs (fever, any fast breathing including those in 0–6 days of age and severe chest indrawing) may not need referral to a hospital. Additionally, those with multiple signs of systemic infection need more attention, irrespective of PSBI sub-categorization. More research is needed to address these issues, which can inform decisions about further improving PSBI management.

Fourth, high early neonatal mortality rate is also linked with complications in pregnancy, labour and post-partum, so there it is essential to timely identify high-risk pregnancies and manage them in suitable high dependency and critical care settings in low and middle-income countries [48,49], which is challenging. Finally, prompt identification and diagnosis of neonatal sepsis require antibiotics and supportive treatment. Inappropriate antibiotic use contributes to antimicrobial resistance, which is quite widespread even in the high-income countries and is one of the greatest public health challenges of the 21st century [50]. Antibiotic stewardship is essential and health professionals treating sepsis should have the knowledge and follow the recommended antibiotic practices in light of the increasing antimicrobial resistance and avoid using unsuitable treatments [51,52].

Strengths

Our study had several strengths. First, we used population-based surveillance data of young infants collected at five rural sites from three sub-Saharan African countries. Second, it was conducted in a large population from which community-level data was collected prospectively to calculate the risk of death and mortality rates for individual signs of infection in infants up to two months of age in sub-Saharan Africa. Third, CHWs/CHEWs were able to complete at least two postnatal visits in 99% of live births. Fourth, we used longitudinal analyses to evaluate the effect of a sign of infection on survival status during the subsequent visit and used infant-periods rather than individual infants as the unit of comparison allowing for risk of death to be stratified by a visit.

Limitations

However, our study also had some limitations. First, no laboratory investigations or radiological studies were performed to confirm the diagnosis. Second, we did not validate the clinical findings of CHWs/CHEWs. Third, CHWs/CHEWs did not collect information on treatment status. Lastly, we did not collect information on environmental and genetic factors, congenital malformations and other comorbidities, or breastfeeding patterns with which to adjust our regression model.

Conclusion

Signs of infections are common in the first two months of life. The mortality risk differs with clinical signs and can be grouped as very low (local infections, fast breathing 7–59 days), low (fever, severe chest indrawing and fast breathing 0–6 days), moderate (low body temperature and stopped feeding well/not able to feed at all) and high (for movements only on stimulation or no movements at all and multiple signs of infection). New treatment strategies that consider differential mortality risk could be developed and evaluated based on these findings.

Data Availability

The complete de-identified patient data set cannot be shared publicly due to institutional restrictions. However, upon receipt of a proposal with rationale for use and agreement to abide by WHO data access policies, data can be obtained from the primary author YBN (nisary@who.int) or Nicole Grillon (grillonn@who.int), Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva.

Funding Statement

The study was funded by a grant from the Bill & Melinda Gates Foundation to WHO, which sponsored the study.

References

  • 1.United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels and Trends in Child Mortality: Report 2019, Estimates developed by the United Nations Inter-agency Group for Child Mortality Estimation. New York, USA: United Nations Children’s Fund 2019 (Avaialble at https://childmortality.org/wp-content/uploads/2019/09/UN-IGME-Child-Mortality-Report-2019.pdf).
  • 2.Alliance for Maternal and Newborn Health Improvement (AMANHI) mortality study group. Population-based rates, timing, and causes of maternal deaths, stillbirths, and neonatal deaths in south Asia and sub-Saharan Africa: a multi-country prospective cohort study. Lancet Glob Health. 2018;6(12):e1297–e308. Epub 2018/10/27. 10.1016/S2214-109X(18)30385-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.WHO Global Maternal Sepsis Study (GLOSS) Research Group. Frequency and management of maternal infection in health facilities in 52 countries (GLOSS): a 1-week inception cohort study. Lancet Glob Health. 2020;8(5):e661–e71. Epub 2020/05/01. 10.1016/S2214-109X(20)30109-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chu K, Maine R, Trelles M. Cesarean section surgical site infections in sub-Saharan Africa: a multi-country study from Medecins Sans Frontieres. World J Surg. 2015;39(2):350–5. Epub 2014/11/02. 10.1007/s00268-014-2840-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Di Gennaro F, Marotta C, Pisani L, Veronese N, Pisani V, Lippolis V, et al. Maternal caesarean section infection (MACSI) in Sierra Leone: a case-control study. Epidemiol Infect. 2020;148:e40 Epub 2020/02/28. 10.1017/S0950268820000370 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Seale AC, Blencowe H, Manu AA, Nair H, Bahl R, Qazi SA, et al. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(8):731–41. Epub 2014/06/30. 10.1016/S1473-3099(14)70804-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hibberd PL, Hansen NI, Wang ME, Goudar SS, Pasha O, Esamai F, et al. Trends in the incidence of possible severe bacterial infection and case fatality rates in rural communities in Sub-Saharan Africa, South Asia and Latin America, 2010–2013: a multicenter prospective cohort study. Reproductive health. 2016;13(1):65–. 10.1186/s12978-016-0177-1 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.The WHO Young Infants Study Group. Clinical prediction of serious bacterial infections in young infants in developing countries. The Pediatric infectious disease journal. 1999;18(10 Suppl):S23–31. Epub 1999/10/26. 10.1097/00006454-199910001-00005 . [DOI] [PubMed] [Google Scholar]
  • 9.World Health Organization. World Health Organization. Handbook: IMCI integrated management of childhood illness. Geneva: WHO, 2005. (Available at: https://apps.who.int/iris/bitstream/handle/10665/42939/9241546441.pdf;sequence=1). [Google Scholar]
  • 10.Young Infants Clinical Signs Study Group. Clinical signs that predict severe illness in children under age 2 months: a multicentre study. Lancet. 2008;371(9607):135–42. Epub 2008/01/15. 10.1016/S0140-6736(08)60106-3 . [DOI] [PubMed] [Google Scholar]
  • 11.World Health Organization. Integrated Management of Childhood Illness (IMCI): Chart Booklet. Geneva, Switzerland: WHO, 2014. (Available at: https://www.who.int/maternal_child_adolescent/documents/IMCI_chartbooklet/en/). [Google Scholar]
  • 12.Bhandari N, Bahl R, Bhatnagar V, Bhan MK. Treating sick young infants in urban slum setting. Lancet. 1996;347(9017):1774–5. Epub 1996/06/22. . [PubMed] [Google Scholar]
  • 13.Bang AT, Bang RA, Baitule SB, Reddy MH, Deshmukh MD. Effect of home-based neonatal care and management of sepsis on neonatal mortality: field trial in rural India. Lancet. 1999;354(9194):1955–61. Epub 2000/01/06. 10.1016/S0140-6736(99)03046-9 . [DOI] [PubMed] [Google Scholar]
  • 14.Baqui AH, El-Arifeen S, Darmstadt GL, Ahmed S, Williams EK, Seraji HR, et al. Effect of community-based newborn-care intervention package implemented through two service-delivery strategies in Sylhet district, Bangladesh: a cluster-randomised controlled trial. Lancet. 2008;371(9628):1936–44. Epub 2008/06/10. 10.1016/S0140-6736(08)60835-1 . [DOI] [PubMed] [Google Scholar]
  • 15.Zaidi AK, Tikmani SS, Warraich HJ, Darmstadt GL, Bhutta ZA, Sultana S, et al. Community-based treatment of serious bacterial infections in newborns and young infants: a randomized controlled trial assessing three antibiotic regimens. The Pediatric infectious disease journal. 2012;31(7):667–72. Epub 2012/04/07. 10.1097/INF.0b013e318256f86c . [DOI] [PubMed] [Google Scholar]
  • 16.Tshefu A, Lokangaka A, Ngaima S, Engmann C, Esamai F, Gisore P, et al. Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial. Lancet. 2015;385(9979):1758–66. Epub 2015/04/07. 10.1016/S0140-6736(14)62285-6 . [DOI] [PubMed] [Google Scholar]
  • 17.Tshefu A, Lokangaka A, Ngaima S, Engmann C, Esamai F, Gisore P, et al. Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet. 2015;385(9979):1767–76. Epub 2015/04/07. 10.1016/S0140-6736(14)62284-4 . [DOI] [PubMed] [Google Scholar]
  • 18.Baqui AH, Saha SK, Ahmed AS, Shahidullah M, Quasem I, Roth DE, et al. Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet Glob Health. 2015;3(5):e279–87. Epub 2015/04/07. 10.1016/S2214-109X(14)70347-X . [DOI] [PubMed] [Google Scholar]
  • 19.Mir F, Nisar I, Tikmani SS, Baloch B, Shakoor S, Jehan F, et al. Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial. Lancet Glob Health. 2017;5(2):e177–e85. Epub 2016/12/19. 10.1016/S2214-109X(16)30335-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.World Health Organization. Guideline: Managing possible serious bacterial infection in young infants when referral is not feasible. Switzerland: WHO, 2015. (Available at: https://apps.who.int/iris/bitstream/handle/10665/181426/9789241509268_eng.pdf). [PubMed] [Google Scholar]
  • 21.Bang AT, Bang RA, Reddy MH, Baitule SB, Deshmukh MD, Paul VK, et al. Simple clinical criteria to identify sepsis or pneumonia in neonates in the community needing treatment or referral. The Pediatric infectious disease journal. 2005;24(4):335–41. 10.1097/01.inf.0000157094.43609.17 . [DOI] [PubMed] [Google Scholar]
  • 22.Khanal S, Sharma J, Gc VS, Dawson P, Houston R, Khadka N, et al. Community health workers can identify and manage possible infections in neonates and young infants: MINI—a model from Nepal. J Health Popul Nutr. 2011;29(3):255–64. Epub 2011/07/20. 10.3329/jhpn.v29i3.7873 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Baqui AH, Arifeen SE, Rosen HE, Mannan I, Rahman SM, Al-Mahmud AB, et al. Community-based validation of assessment of newborn illnesses by trained community health workers in Sylhet district of Bangladesh. Trop Med Int Health. 2009;14(12):1448–56. Epub 2009/10/08. 10.1111/j.1365-3156.2009.02397.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Darmstadt GL, Baqui AH, Choi Y, Bari S, Rahman SM, Mannan I, et al. Validation of community health workers’ assessment of neonatal illness in rural Bangladesh. Bull World Health Organ. 2009;87(1):12–9. Epub 2009/02/07. 10.2471/blt.07.050666 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Darmstadt GL, Baqui AH, Choi Y, Bari S, Rahman SM, Mannan I, et al. Validation of a clinical algorithm to identify neonates with severe illness during routine household visits in rural Bangladesh. Arch Dis Child. 2011;96(12):1140–6. Epub 2011/10/04. 10.1136/archdischild-2011-300591 . [DOI] [PubMed] [Google Scholar]
  • 26.Mullany LC, Darmstadt GL, Katz J, Khatry SK, LeClerq SC, Adhikari RK, et al. Development of clinical sign based algorithms for community based assessment of omphalitis. Arch Dis Child Fetal Neonatal Ed. 2006;91(2):F99–104. Epub 2005/10/15. 10.1136/adc.2005.080093 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.AFRIcan NEonatal Sepsis Trial Group. Treatment of fast breathing in neonates and young infants with oral amoxicillin compared with penicillin-gentamicin combination: study protocol for a randomized, open-label equivalence trial. The Pediatric infectious disease journal. 2013;32 Suppl 1:S33–8. Epub 2013/08/24. 10.1097/INF.0b013e31829ff7eb [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.AFRIcan NEonatal Sepsis Trial Group. Simplified regimens for management of neonates and young infants with severe infection when hospital admission is not possible: study protocol for a randomized, open-label equivalence trial. The Pediatric infectious disease journal. 2013;32 Suppl 1:S26–32. Epub 2013/08/24. 10.1097/INF.0b013e31829ff7d1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wall SN, Mazzeo CI, Adejuyigbe EA, Ayede AI, Bahl R, Baqui AH, et al. Ensuring quality in AFRINEST and SATT: clinical standardization and monitoring. The Pediatric infectious disease journal. 2013;32 Suppl 1:S39–45. Epub 2013/10/18. 10.1097/INF.0b013e31829ff801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.World Health Organization, UNICEF. Integrated Management of Childhood Illness: caring for newborns and children in the community. Switzerland: WHO & UNICEF, 2011. [Google Scholar]
  • 31.World Health Organization. Recommendations on postnatal care of the mother and newborn. Geneva, Switzerland: WHO, 2013. [PubMed] [Google Scholar]
  • 32.Requejo J, Diaz T, Park L, Chou D, Choudhury A, Guthold R, et al. Assessing coverage of interventions for reproductive, maternal, newborn, child, and adolescent health and nutrition. BMJ. 2020;368:l6915 Epub 2020/01/28. 10.1136/bmj.l6915 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Guenther T, Mopiwa G, Nsona H, Qazi S, Makuluni R, Fundani CB, et al. Feasibility of implementing the World Health Organization case management guideline for possible serious bacterial infection among young infants in Ntcheu district, Malawi. PLoS One. 2020;15(4):e0229248 Epub 2020/04/15. 10.1371/journal.pone.0229248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wammanda RD, Adamu SA, Joshua HD, Nisar YB, Qazi SA, Aboubaker S, et al. Implementation of the WHO guideline on treatment of young infants with signs of possible serious bacterial infection when hospital referral is not feasible in rural Zaria, Nigeria: Challenges and solutions. PLoS One. 2020;15(3):e0228718 Epub 2020/03/11. 10.1371/journal.pone.0228718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kozuki N, Guenther T, Vaz L, Moran A, Soofi SB, Kayemba CN, et al. A systematic review of community-to-facility neonatal referral completion rates in Africa and Asia. BMC Public Health. 2015;15:989 Epub 2015/10/01. 10.1186/s12889-015-2330-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Owais A, Sultana S, Stein AD, Bashir NH, Awaldad R, Zaidi AK. Why do families of sick newborns accept hospital care? A community-based cohort study in Karachi, Pakistan. J Perinatol. 2011;31(9):586–92. Epub 2011/01/29. 10.1038/jp.2010.191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Munthali AC, Mannan H, MacLachlan M, Swartz L, Makupe CM, Chilimampunga C. Non-use of Formal Health Services in Malawi: Perceptions from Non-users. Malawi Med J. 2014;26(4):126–32. Epub 2015/07/15. [PMC free article] [PubMed] [Google Scholar]
  • 38.Lunze K, Bloom DE, Jamison DT, Hamer DH. The global burden of neonatal hypothermia: systematic review of a major challenge for newborn survival. BMC Medicine. 2013;11(1):24 10.1186/1741-7015-11-24 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Mullany LC. Neonatal hypothermia in low-resource settings. Semin Perinatol. 2010;34(6):426–33. Epub 2010/11/26. 10.1053/j.semperi.2010.09.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lunze K, Hamer DH. Thermal protection of the newborn in resource-limited environments. J Perinatol. 2012;32(5):317–24. Epub 2012/03/03. 10.1038/jp.2012.11 . [DOI] [PubMed] [Google Scholar]
  • 41.Bang AT, Reddy HM, Baitule SB, Deshmukh MD, Bang RA. The incidence of morbidities in a cohort of neonates in rural Gadchiroli, India: seasonal and temporal variation and a hypothesis about prevention. J Perinatol. 2005;25 Suppl 1:S18–28. Epub 2005/03/26. 10.1038/sj.jp.7211271 . [DOI] [PubMed] [Google Scholar]
  • 42.Christensson K, Bhat GJ, Eriksson B, Shilalukey-Ngoma MP, Sterky G. The effect of routine hospital care on the health of hypothermic newborn infants in Zambia. J Trop Pediatr. 1995;41(4):210–4. Epub 1995/08/01. 10.1093/tropej/41.4.210 . [DOI] [PubMed] [Google Scholar]
  • 43.da Mota Silveira SM, Goncalves de Mello MJ, de Arruda Vidal S, de Frias PG, Cattaneo A. Hypothermia on admission: a risk factor for death in newborns referred to the Pernambuco Institute of Mother and Child Health. J Trop Pediatr. 2003;49(2):115–20. Epub 2003/05/06. 10.1093/tropej/49.2.115 . [DOI] [PubMed] [Google Scholar]
  • 44.Kambarami R, Chidede O. Neonatal hypothermia levels and risk factors for mortality in a tropical country. Cent Afr J Med. 2003;49(9–10):103–6. Epub 2004/08/10. . [PubMed] [Google Scholar]
  • 45.Johanson RB, Malla DS, Tuladhar C, Amatya M, Spencer SA, Rolfe P. A survey of technology and temperature control on a neonatal unit in Kathmandu, Nepal. J Trop Pediatr. 1993;39(1):4–10. Epub 1993/02/01. 10.1093/tropej/39.1.4 . [DOI] [PubMed] [Google Scholar]
  • 46.Mathur NB, Krishnamurthy S, Mishra TK. Evaluation of WHO classification of hypothermia in sick extramural neonates as predictor of fatality. J Trop Pediatr. 2005;51(6):341–5. Epub 2005/07/15. 10.1093/tropej/fmi049 . [DOI] [PubMed] [Google Scholar]
  • 47.World Health Organization. Integrated Management of Childhood Illness: management of the sick young infant aged up to 2 months. IMCI chart booklet. Geneva, Switzerland: WHO, 2019. (Available at: https://www.who.int/maternal_child_adolescent/documents/management-sick-young-infant-0-2-months/en/). [Google Scholar]
  • 48.Vasco M, Pandya S, Van Dyk D, Bishop DG, Wise R, Dyer RA. Maternal critical care in resource-limited settings. Narrative review. Int J Obstet Anesth. 2019;37:86–95. Epub 2018/11/30. 10.1016/j.ijoa.2018.09.010 . [DOI] [PubMed] [Google Scholar]
  • 49.Marotta C, Pisani L, Di Gennaro F, Cavallin F, Bah S, Pisani V, et al. Epidemiology, Outcomes, and Risk Factors for Mortality in Critically Ill Women Admitted to an Obstetric High-Dependency Unit in Sierra Leone. Am J Trop Med Hyg. 2020;103(5):2142–8. Epub 2020/08/26. 10.4269/ajtmh.20-0623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. Epub 2018/11/10. 10.1016/S1473-3099(18)30605-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Di Gennaro F, Marotta C, Amicone M, Bavaro DF, Bernaudo F, Frisicale EM, et al. Italian young doctors’ knowledge, attitudes and practices on antibiotic use and resistance: A national cross-sectional survey. J Glob Antimicrob Resist. 2020;23:167–73. Epub 2020/09/25. 10.1016/j.jgar.2020.08.022 . [DOI] [PubMed] [Google Scholar]
  • 52.Pulcini C, Williams F, Molinari N, Davey P, Nathwani D. Junior doctors’ knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. Clin Microbiol Infect. 2011;17(1):80–7. Epub 2010/02/06. 10.1111/j.1469-0691.2010.03179.x . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Claudia Marotta

8 Jan 2021

PONE-D-20-16849

Prevalence of clinical signs of possible serious bacterial infection and mortality associated with them from a population-based surveillance of young infants from birth to 2 months of age

PLOS ONE

Dear Dr. NIsar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 20 January. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Claudia Marotta

Academic Editor

PLOS ONE

Additional Editor Comments:

dear authors follow reviewer suggestion to improve your paper

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I read the manuscript in 1 hour. I'm enthusiastic about the manuscript. I find it well wrote and with important topic.

Below my suggestions

1. Introduction: well done. underline better also the role of maternal cesarian section infection and how it is important also for maternal and neonatal outome expecially in low setting (see and cite this paper from Sierra Leone Di Gennaro F, Maternal caesarean section infection (MACSI) in Sierra Leone: a case-control study. Epidemiol Infect. 2020 Feb 27;148:e40. doi: 10.1017/S0950268820000370. PMID: 32102721; PMCID: PMC7058652.) and how maternal and neonatal outcomes are strongly related.

2. Methods well wrote

3. Results: no comment

4. Discussion: underline the lack of microbiological test for the identification of responsible germs and a better antibiotic therapy and identification of resistance. I believe there is a need to advocate on the development of microbiology in these contexts. Underline also the need to develop an Intensive Care unit for maternal and neonatal ( see and cite this experience

Epidemiology, Outcomes, and Risk Factors for Mortality in Critically Ill Women Admitted to an Obstetric High-Dependency Unit in Sierra Leone. Am J Trop Med Hyg. 2020 Nov;103(5):2142-2148. doi: 10.4269/ajtmh.20-0623. PMID: 32840199; PMCID: PMC7646769. and Cost-Utility of Intermediate Obstetric Critical Care in a Resource-Limited Setting: A Value-Based Analysis. Ann Glob Health. 2020 Jul 20;86(1):82. doi: 10.5334/aogh.2907. PMID: 32742940; PMCID: PMC7380057.)

Also highlithed the need for doctors to train themselves on the topics of antibiotic therapy, antimicrobial stewardship because the role of sepsis in neonatal and maternal deaths is very high (doi: 10.1016/j.jgar.2020.08.022. Epub ahead of print. PMID: 32971291.)

Reviewer #2: Few cocnerns:

1- Hypothermia is defined in your study as < 35.5, and

but the WHO its publication as well as in US NWN nurseries and defined by AAP, hypothermia in neonates is < 36.5 (few centers refer to 36.3). Please expailn why you use lower temp Also, if you use WHO definition as listed below, tjhat can completely change incidence of morbidity among the population you visited:

https://apps.who.int/iris/bitstream/handle/10665/60042/WHO_FHE_MSM_93.2.pdf;jsessionid=08EF4625562B4D043C61B201EEFE6C26?sequence=1

* keep in your mind: In newborns, the rectal temperature was equal to the axillary temperature plus 0.2 degrees C for each week of age up to 5 weeks. DOI: 10.1001/archpedi.1996.02170260078013

2- for Signs of Systemic Infection:

Our authors did not mention color change :

- Jaundice other than physiologic one (prolonged and deep color)

- Cyanosis (central)

- Skin rash

- excessive losing Body weight compared to birth weight, which is a sign of underlying pathology vs. malnutrition.

? please explain

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Claudia Marotta

8 Feb 2021

Prevalence of clinical signs of possible serious bacterial infection and mortality associated with them from population-based surveillance of young infants from birth to 2 months of age

PONE-D-20-16849R1

Dear Dr. Yasir,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Claudia Marotta

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

dear Authors congratulations

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors improved they already good paper. I find a very good manuscript and agree to publish it

The research topic is relevant and also the setting of study

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Claudia Marotta

9 Feb 2021

PONE-D-20-16849R1

Prevalence of clinical signs of possible serious bacterial infection and mortality associated with them from population-based surveillance of young infants from birth to 2 months of age

Dear Dr. Nisar:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Claudia Marotta

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: 2021-1-13_Rebuttal letter_PONE-D-20-16849.docx

    Data Availability Statement

    The complete de-identified patient data set cannot be shared publicly due to institutional restrictions. However, upon receipt of a proposal with rationale for use and agreement to abide by WHO data access policies, data can be obtained from the primary author YBN (nisary@who.int) or Nicole Grillon (grillonn@who.int), Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES